Define the role of REV-ERB in colonic RORgt+ regulatory T cells

项目摘要 调节性T细胞（Treg）在保持免疫系统平衡和预防免疫系统疾病方面起着至关重要的作用。 自身免疫性疾病Treg功能缺陷导致自身免疫性疾病，而肿瘤内的Treg可以阻断 有效的抗肿瘤免疫应答。在适应组织的过程中， 微环境最近的研究表明，一个独特的RORgt（维甲酸相关孤儿受体γ）， t）可以在结肠固有层中诱导表达Treg细胞群。这些RORgt + THEORY扮演一个 在抑制结肠炎症中的重要作用。在Treg细胞中，REV-ERBa在RORgt+中高度表达。 结肠T淋巴细胞，但不存在于RORgt-结肠T淋巴细胞或脾T淋巴细胞中。Treg特异性REV-ERB缺失的小鼠 对TNBS诱导的结肠炎更敏感，RORgt + Treg细胞减少，Th1/Th17细胞增加。 介导的结肠炎症。RNA测序实验表明，一组基因的表达 在REV-ERB缺陷的结肠T细胞中，与Treg功能相关的细胞因子，包括CTLA-4、IL-10和c-Maf， 与WT对照相比。为了研究REV-ERB在Tumor中的基因调控机制，郑博士实验室 使用Foxp3、REV-ERBa和RORgt抗体，用WT RORgt + iTclad进行Cut & Run测定，以定位 它们的结合峰值在全基因组范围内。结果表明，这3种化合物的结合峰有明显重叠 转录因子，表明Treg中Foxp3，REV-ERB和RORgt之间的基因调控协调 细胞拟议研究的总体目标是确定REV-ERB在Treg功能中的作用。这一目标将 通过剖析RORgt + Treg细胞中REV-ERB功能的分子机制来实现（目的1）， 以及表征IBD小鼠模型中REV-ERB在Treg中的作用（目的2）。拟议会议的成果 这些研究有望揭示REV-ERB在RORgt + THBE中的功能和机制作用。这样的结果 预计将进一步推进我们对RORgt + TdR的身份和功能如何建立的理解 并保持。此外，这项研究将提供关键的见解，如何转录阻遏物，如REV- ERB是调节Treg细胞转录激活因子功能的关键因子。最后，结果 这项研究的结果可以为开发针对IBD的REV-ERB治疗药物提供证据 治疗

PROJECT SUMMARY Regulatory T cells (Treg) play a crucial role in keeping the immune system in balance and preventing autoimmune disease. Defective Treg function leads to autoimmune diseases, while intra-tumor Tregs can block effective anti-tumor immune responses. Tregs can undergo further specialization in adaptation to their tissue microenvironment. Recent studies showed that a unique RORgt (retinoic acid–related orphan receptor gamma t) expressing Treg cell population could be induced in the colon lamina propria. These RORgt+ Tregs play an important role in the suppression of colon inflammation. In Treg cells, REV-ERBa is highly expressed in RORgt+ colonic Tregs, but not in RORgt- colonic Tregs or spleen Tregs. Mice with Treg-specific deletion of REV-ERB were more susceptible to TNBS-induced colitis with decreased RORgt+ Treg cells and increased Th1/Th17 cell- mediated inflammation in the colon. RNA-sequencing experiment showed that the expression of a set of genes related to Treg function, including CTLA-4, IL-10, and c-Maf, were reduced in REV-ERB deficient colonic Tregs compared to WT controls. To study the mechanism of gene regulation by REV-ERB in Tregs, Dr. Zheng’s lab performed Cut & Run assays with WT RORgt+ iTregs using Foxp3, REV-ERBa, and RORgt antibodies to map their binding peaks genome-wide. The results showed a significant overlap of the binding peaks of these 3 transcription factors, suggesting coordination in gene regulation among Foxp3, REV-ERB, and RORgt in Treg cells. The overall objective of the proposed study is to define the role of REV-ERB in Treg function. This goal will be accomplished by dissecting the molecular mechanism of REV-ERB function in RORgt+ Treg cells (Aim 1), and characterizing the role of REV-ERB in Treg in mouse models of IBD (Aim 2). The outcomes of the proposed study are expected to reveal the functional and mechanistic role of REV-ERB in RORgt+ Tregs. Such results are expected to further advance our understanding of how the identity and function of RORgt+ Tregs are established and maintained. Additionally, this study will provide key insights into how transcriptional repressor such as REV- ERB serves as key regulator and tune the function of transcriptional activators in Treg cells. Finally, the outcomes of this study could provide evidence supporting the development of therapeutics targeting REV-ERB for IBD treatment.